Sign up to save your podcasts
Or
Share Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations
Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.
A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754
What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160
View all episodes
By John Bossaer
4.9
185185 ratings
Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.
A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754
What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160
More shows like OncoPharm
View all
JAMA Clinical Reviews
504 Listeners
The Daily
113,475 Listeners
Up First from NPR
56,978 Listeners
Armchair Expert with Dax Shepard
69,594 Listeners
ASCO Guidelines
47 Listeners
The Peter Attia Drive
7,956 Listeners
OncLive® On Air
23 Listeners
Raising Good Humans
1,883 Listeners
Oncology Today with Dr Neil Love
61 Listeners
Huberman Lab
29,306 Listeners
The Money with Katie Show
1,539 Listeners
Two Onc Docs
196 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
47 Listeners
WolverHeme Happy Hour
30 Listeners
Good Hang with Amy Poehler
12,549 Listeners